-
公开(公告)号：US20050025742A1
公开(公告)日：2005-02-03
申请号：US10861654
申请日：2004-06-04
IPC分类号： A61K20060101 , A61K9/00 , A61K38/21 , A61K48/00
CPC分类号： A61K9/0034 , A61K38/21
摘要： Methods and pharmaceutical compositions for administering protein or gene therapy to tissues or organs having an epithelial cell layer are provided. A protein or nucleic acid encoding the protein is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the delivery of the interferon or nucleic acid to the cells of the target tissues or organs. The methods and combinations are particularly useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an alpha-interferon or a gene delivery system encoding the interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 10 to 1000 fold increased in interferon levels and activity may be observed with the use of a SYN3 formulation as opposed to a PBS formulation of the same interferon protein or interferon gene delivery system.
摘要翻译： 提供了用于对具有上皮细胞层的组织或器官进行蛋白质或基因治疗的方法和药物组合物。 将编码蛋白质的蛋白质或核酸与目标组织或器官联合施用递送增强剂的组合施用，所述递送增强剂增加干扰素或核酸向靶组织或器官的细胞递送。 所述方法和组合在治疗癌症和其它对干扰素治疗有反应的病症方面特别有用。 示例性方法包括向膀胱经尿道膀胱内施用治疗有效量的药物组合物，其包含α-干扰素或编码干扰素和SYN3或SYN3同源物或类似物的基因递送系统。 在膀胱中，与使用相同干扰素蛋白或干扰素基因递送系统的PBS制剂相比，使用SYN3制剂可以观察到高达10至1000倍的干扰素水平和活性。
-
公开(公告)号：US20060199782A1
公开(公告)日：2006-09-07
申请号：US11359997
申请日：2006-02-21
IPC分类号： A61K48/00 , A61K31/704 , A61K31/56
CPC分类号： A61K48/00
摘要： A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
摘要翻译： 一种用于增强治疗剂转移至细胞的方法和药物组合物，其中所述治疗剂配制在包含式I化合物的缓冲液中：其中：n为2-8的整数; X 1是胆酸基或脱氧胆酸基; X 2和X 3各自独立地选自胆酸基，脱氧胆酸基和糖基，其中选择糖基团 从戊糖单糖组，己糖单糖组，戊糖 - 戊糖二糖基团，己糖 - 六糖基团，戊糖 - 六糖二糖基团和己糖 - 戊糖二糖基团组成的组; 并且其中X 2和X 3中的至少一个是糖基团。
-
公开(公告)号：US20110104118A1
公开(公告)日：2011-05-05
申请号：US12912496
申请日：2010-10-26
CPC分类号： A61K47/186 , A61K9/0019 , A61K38/1709 , A61K47/10 , A61K48/00 , C07K14/4736 , C07K14/4746 , C12N15/87 , C12N2799/022
摘要： A method and pharmaceutical composition for the treatment of cancer using a gene delivery system, such as a viral vector delivery system, comprising a therapeutic gene such as p53 or a retinoblastoma tumor suppressor gene wherein the gene delivery system is formulated in a buffer comprising a delivery-enhancing agent such as ethanol or a detergent.
摘要翻译： 一种用于使用基因递送系统（例如病毒载体递送系统）治疗癌症的方法和药物组合物，其包含治疗性基因如p53或成视网膜细胞瘤肿瘤抑制基因，其中所述基因递送系统配制在包含递送 - 增强剂如乙醇或洗涤剂。
-
公开(公告)号：US07002027B1
公开(公告)日：2006-02-21
申请号：US08889355
申请日：1997-07-08
CPC分类号： A61K48/00
摘要： The present invention is directed to compositions and methods of treating cancer by gene therapy using a therapeutic gene formulated in a buffer comprising a delivery-enhancing agent. The delivery-enhancing agents of the invention can be used to formulate therapeutic or diagnostic agents, such as proteins, nucleic acids, antisense RNA, small molecules, etc., for administration to any tissue or organ having an epithelial membrane. The delivery-enhancing agents include detergents, alcohols, surfactants and other molecules.
摘要翻译： 本发明涉及通过使用配制在包含递送增强剂的缓冲液中的治疗基因进行基因治疗来治疗癌症的组合物和方法。 本发明的递送增强剂可用于配制治疗或诊断试剂，例如蛋白质，核酸，反义RNA，小分子等，用于给予具有上皮膜的任何组织或器官。 递送增强剂包括洗涤剂，醇，表面活性剂和其它分子。
-
公开(公告)号：US4600721A
公开(公告)日：1986-07-15
申请号：US716408
申请日：1985-03-27
申请人： Peter Morsdorf , Helmut Schickaneder , Heidrun Engler , Istvan Szelenyi , Kurt H. Ahrens , Kay Brune
发明人： Peter Morsdorf , Helmut Schickaneder , Heidrun Engler , Istvan Szelenyi , Kurt H. Ahrens , Kay Brune
IPC分类号： A61K31/42 , A61K31/423 , A61K31/425 , A61K31/428 , A61P11/00 , A61P17/00 , A61P27/02 , A61P27/14 , A61P29/00 , A61P37/08 , A61P43/00 , C07D263/58 , C07D277/82
CPC分类号： C07D263/58 , A61K31/42 , A61K31/425 , C07D277/82
摘要： Pharmaceutical preparations having an antiphlogistic action are described. The preparations contain, as active ingredient, a benzazole derivative corresponding to the general tautomeric formulae I ##STR1## wherein X represents a sulphur or oxygen atom and R.sup.1 represents a hydrogen atom and R.sup.2 a hydroxymethyl, formyl, lower carbalkoxy or lower acyl group or R.sup.1 and R.sup.2 together represent the group ##STR2## wherein R.sup.3 and R.sup.4 denote, independently of one another, a hydrogen atom or a C.sub.1 -C.sub.6 -alkyl group, or they contain a physiologically acceptable salt thereof. These pharmaceutical preparations are suitable in particular for the treatment of inflammatory conditions and for inhibiting the lipoxygenase and/or cyclooxygenase route of arachidonic acid metabolism.
摘要翻译： 描述具有消炎作用的药物制剂。 该制剂含有作为活性成分的对应于一般互变异构体I（I）的苯并唑衍生物，其中X表示硫或氧原子，R1表示氢原子，R2表示羟甲基，甲酰基，低级烷氧羰基或低级酰基 基团或R 1和R 2一起表示基团
，其中R 3和R 4彼此独立地表示氢原子或C 1 -C 6烷基，或它们含有其生理上可接受的盐。 这些药物制剂特别适用于治疗炎性病症和抑制花生四烯酸代谢的脂氧合酶和/或环氧合酶途径。 -
公开(公告)号：US20100028431A1
公开(公告)日：2010-02-04
申请号：US12422807
申请日：2009-04-13
IPC分类号： A61K9/10 , A61K31/70 , A61K31/7016 , A61K38/16 , A61K31/7088 , C08B37/00 , A61P35/00
CPC分类号： A61K48/00
摘要： A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
摘要翻译： 一种用于增强治疗剂转移至细胞的方法和药物组合物，其中所述治疗剂配制在包含式I化合物的缓冲液中：其中：n为2-8的整数; X1是胆酸基或脱氧胆酸基; X2和X3各自独立地选自胆酸基，脱氧胆酸基和糖基，其中所述糖基选自戊糖单糖基，己糖单糖基，戊糖 - 戊糖基 二糖基团，己糖 - 己糖二糖基团，戊糖 - 己糖二糖基团和己糖 - 六糖二糖基团; 并且其中X 2和X 3中的至少一个是糖基团。
-
7.发明授权Dihydropyridazinone derivatives, a process for their preparation and pharmaceutical preparations containing these compounds 失效二氢哒嗪酮衍生物，其制备方法和含有这些化合物的药物制剂
公开(公告)号：US4921856A
公开(公告)日：1990-05-01
申请号：US176689
申请日：1988-04-01
IPC分类号： A61K31/50 , A61P9/04 , C07D237/04 , C07D403/10 , C07D403/12
CPC分类号： C07D403/10 , C07D237/04 , C07D403/12
摘要： New dihydropryidazinone derivatives corresponding to the following formula ##STR1## and a process for their preparation and pharmaceutical preparations containing these compounds are described. These compounds are effective positively inotropic substances with an improved therapeutic profile.
摘要翻译： 描述了对应于下式（I）的新的二氢哒嗪酮衍生物及其制备方法和含有这些化合物的药物制剂。 这些化合物是具有改善的治疗特征的有效的正性肌力物质。
-
公开(公告)号：US07538093B2
公开(公告)日：2009-05-26
申请号：US11359997
申请日：2006-02-21
CPC分类号： A61K48/00
摘要： A method and pharmaceutical composition for the enhancement of transfer of a therapeutic agent to a cell wherein the therapeutic agent is formulated in a buffer comprising a compound of Formula I: wherein: n is an integer from 2-8; X1 is a cholic acid group or deoxycholic acid group; and X2 and X3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups; and wherein at least one of X2 and X3 is a saccharide group.
摘要翻译： 一种用于增强治疗剂转移至细胞的方法和药物组合物，其中所述治疗剂配制在包含式I化合物的缓冲液中：其中：n为2-8的整数; X1是胆酸基或脱氧胆酸基; X2和X3各自独立地选自胆酸基，脱氧胆酸基和糖基，其中所述糖基选自戊糖单糖基，己糖单糖基，戊糖 - 戊糖基 二糖基团，己糖 - 己糖二糖基团，戊糖 - 己糖二糖基团和己糖 - 六糖二糖基团; 并且其中X 2和X 3中的至少一个是糖基团。
-
公开(公告)号：US07534769B2
公开(公告)日：2009-05-19
申请号：US10055863
申请日：2002-01-22
CPC分类号： A61K31/56 , A61K31/7008 , A61K48/00 , C07J9/005 , C07J41/0061 , C12N15/87
摘要： This invention provides methods and compositions for enhancing transfer of an agent into a cell. The agents can include polypeptides, polynucleotides such as genes and antisense nucleic acids, and other molecules. In some embodiments, the agents are modulating agents that can modulate a cellular activity or function when introduced into the cell. The methods and compositions are useful for introducing agents into individual cells, as well as cells that are present as a tissue or organ.
-
公开(公告)号：US20050014259A1
公开(公告)日：2005-01-20
申请号：US10913567
申请日：2004-08-06
申请人： Susan Conroy , Heidrun Engler , Daniel Maneval
发明人： Susan Conroy , Heidrun Engler , Daniel Maneval
IPC分类号： A61K31/715 , A61K31/724 , A61K48/00 , C12N15/87 , C12Q1/68 , C12N15/85
CPC分类号： C12N15/87 , A61K31/715 , A61K31/724 , A61K35/761 , A61K38/1758 , A61K48/00 , A61K48/0008 , C12N15/86 , C12N2710/10332 , C12N2710/10343 , Y10S435/932 , A61K2300/00
摘要： The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods of treatment in combination with such formulations.
摘要翻译： 本发明提供了增强核酸向细胞递送的制剂和方法。 包含与糖组合的糊精聚合物的制剂提供增强的核酸递送，特别是真核表达载体，证明核酸在体内增强的细胞递送至细胞。 本发明还提供了与这些制剂组合的治疗方法。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.02 秒)
